Results 241 to 250 of about 1,718,808 (353)

Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer

Molecular Oncology, EarlyView.
This study employed targeted metabolomic profiling to identify 302 distinct metabolites present in platelet‐rich plasma (PRP), revealing aberrant metabolic profiles amongst individuals diagnosed with colorectal cancer (CRC). Compared to carcinoembryonic antigen (CEA) and cancer antigen 19‐9 (CA199), our metabolite panel showed improved sensitivity ...
Zuojian Hu, Fenglin Shen, Yang Liu, Ziqing Zhong, Yongling Chen, Zhiyuan Xia, Cuiju Mo, Hongxiu Yu   +7 more
wiley   +1 more source

A robust and personalized privacy-preserving approach for adaptive clustered federated distillation. [PDF]

Sci Rep
Shawkat M, Ali ZH, Salem M, El-Desoky A.
europepmc   +1 more source

Polyfunctional CD8+CD226+RUNX2hi effector T cells are diminished in advanced stages of chronic lymphocytic leukemia

Molecular Oncology, Volume 19, Issue 5, Page 1347-1370, May 2025.
CD226+CD8+ T cells express elevated levels of RUNX2, exhibit higher proliferation capacity, cytokines and cytolytic molecules expression, and migratory capacity. In contrast, CD226−CD8+ T cells display an exhausted phenotype associated with the increased expression of co‐inhibitory receptors and impaired effector functions.
Maryam Rezaeifar, Shima Shahbaz, Anthea C. Peters, Spencer B. Gibson, Shokrollah Elahi   +4 more
wiley   +1 more source

In Silico-Based Investigation of the Immunogenicity and Biochemical Attributes of <i>Toxoplasma gondii</i> Apical Membrane Antigen 1 (TgAMA1). [PDF]

J Parasitol Res
Foroutan M, Ghaffari AD, Ghaffarifar F, Karimipour-Saryazdi A, Birgani AA, Majidiani H, Cortes H, Elsheikha HM.   +7 more
europepmc   +1 more source

Inhibition of acyl‐CoA synthetase long‐chain isozymes decreases multiple myeloma cell proliferation and causes mitochondrial dysfunction

Molecular Oncology, EarlyView.
Triacsin C inhibition of the acyl‐CoA synthetase long chain (ACSL) family decreases multiple myeloma cell survival, proliferation, mitochondrial respiration, and membrane potential. Made with Biorender.com. Multiple myeloma (MM) is an incurable cancer of plasma cells with a 5‐year survival rate of 59%.
Connor S. Murphy, Heather Fairfield, Victoria E. DeMambro, Samaa Fadel, Carlos A. Gartner, Michelle Karam, Christian Potts, Princess Rodriguez, Ya‐Wei Qiang, Habib Hamidi, Xiangnan Guan, Calvin P. H. Vary, Michaela R. Reagan   +12 more
wiley   +1 more source

Privacy-Preserving Multi-User Graph Intersection Scheme for Wireless Communications in Cloud-Assisted Internet of Things. [PDF]

Sensors (Basel)
Yang S.
europepmc   +1 more source

Cell‐free DNA aneuploidy score as a dynamic early response marker in prostate cancer

Molecular Oncology, EarlyView.
mFast‐SeqS‐based genome‐wide aneuploidy scores are concordant with aneuploidy scores obtained by whole genome sequencing from tumor tissue and can predict response to ARSI treatment at baseline and, at an early time point, to ARSI and taxanes. This assay can be easily performed at low cost and requires little input of cfDNA. Cell‐free circulating tumor
Khrystany T. Isebia, Anouk C. de Jong, Lisanne F. van Dessel, Vanja de Weerd, Corine Beaufort, Jean Helmijr, José Alberto Nakauma‐González, Job van Riet, Paul Hamberg, Daniel Vis, Michiel S. van der Heijden, Nick Beije, Martijn P. Lolkema, Teoman Deger, Saskia M. Wilting, Ronald de Wit, Maurice P. H. M. Jansen, John W. M. Martens   +17 more
wiley   +1 more source

Revolutionizing Chikungunya Vaccines: mRNA Breakthroughs With Molecular and Immune Simulations. [PDF]

Bioinform Biol Insights
Masum MHU, Mahdeen AA, Barua A.
europepmc   +1 more source

CRISPR targeting of FOXL2 c.402C>G mutation reduces malignant phenotype in granulosa tumor cells and identifies anti‐tumoral compounds

Molecular Oncology, Volume 19, Issue 4, Page 1092-1116, April 2025.
FOXL2 c.402C>G mutation drives granulosa cell tumors. Using CRISPR technology, we selectively corrected this mutation, reducing malignancy and increasing sensitivity to dasatinib and ketoconazole. Transcriptomic changes revealed potential therapeutic targets, demonstrating CRISPR's promise for treating this rare ovarian cancer.
Sandra Amarilla‐Quintana, Paloma Navarro, Iván Hernández, Alejandra Ramos, Ana Montero‐Calle, Pablo Cabezas‐Sainz, Maria J Barrero, Diego Megías, Borja Vilaplana‐Martí, Carolina Epifano, Déborah Gómez‐Dominguez, Sara Monzón, Isabel Cuesta, Laura Sánchez, Rodrigo Barderas, Jesús García‐Donas, Alberto Martín, Ignacio Pérez de Castro   +17 more
wiley   +1 more source

Using SDPC for Visual Exploratory Analysis of Semiconductor Production Line Sensor Data. [PDF]

Sensors (Basel)
Li X, Han XH, Sun Y.
europepmc   +1 more source